Sanofi acquires biotech firm Synthorx for $2.5 billion
December 9, 2019Sales and Marketing Genetic Alphabet, Sanofi, acute lymphoblastic leukaemia, leukaemia
Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion). Paul Hudson, …
Transactions in the pharma sector: Through the EU merger review looking-glass
December 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, feature, mergers & acquisitions, pharma
With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …
J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma
December 9, 2019Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma
Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …
FDA investigating if carcinogen NDMA is in diabetes drug
December 6, 2019Medical Communications FDA, Health Canada, MDMA, NDMA, carcinogen, diabetes
The FDA is looking into if the diabetes drug metformin has unsafe levels of a cancer-causing chemical. This comes after …
Sage Therapeutics’ depression drug falls short at Phase 3
December 6, 2019Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure
Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …
Anti-vaxx movement complicit in 140,000 global measles deaths in 2018, mostly in children
December 6, 2019Medical Communications anti vaxx, anti-vaxx, anti-vaxxers, measles mumps polio, measls, mumps, polio, vaccinations, vaccines
Over 140,000 people died from measles last year, with most of them being children under five, according to World Health …
Top Ten most popular articles on Pharmafile.com this week
December 6, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, NHS, corruption, lung cancer, opiods crisis, opioids
Corruption and bribery feature heavily in the news this week. A recently exposed 1997 email chain shows Dr Richard Sackler, …
FDA approves first three generic versions of Novartis’ Gilenya for relapsing multiple sclerosis
December 6, 2019Medical Communications, Sales and Marketing Novartis, generics, gilenya, multiple sclerosis, pharma
The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult …
Partnership with payers: Communicating and negotiating with impact
December 6, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NDA, market access, pharma
NDA’s Lisa Peluso, Director, Coaching and Client Engagement, outlines key strategies for interacting with audiences and payers while maximising team …
Amazon and Novartis team up on cloud services
December 5, 2019Sales and Marketing Amazon Web Services, Cloud services, Novartis, amazon, pharma, product lines
Novartis is teaming up with Amazon Web Services to utilise its cloud computing technology. The collaboration is designed to overhaul …
Dr Richard Torbett is named as the new Chief Executive of the ABPI
December 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its new Chief Executive. He will …
English patient diagnosed with monkeypox after returning from Nigeria
December 5, 2019Medical Communications Disease, chickenpox, monkeypox
A person has been diagnosed with the rare viral infection monkeypox in South West England. It is believed they contracted …
Seizures of black market diazepam tablets double in the UK in a year
December 5, 2019Manufacturing and Production Border Force, Diazepam, NHS, anxiety, opioids
The number of illegal diazepam tablets seized by the UK Border Force has doubled in a year, going from 545,000 …
FDA-approved drug can repair gut leakiness in types of bowel disease
December 5, 2019Research and Development biomedicine, bowel, bowel cancer, bowel disease
A team of biomedical scientists at the University of California has found that a FDA-approved drug for treating rheumatoid arthritis …
Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine
December 5, 2019Research and Development Allergan, FDA, pharma, ubrogepant
New Phase 3 data has been released showing that both 50mg and 100mg doses of Allergan’s ubrogepant met their primary …
Patient experience: Living with desmoid fibromatosis
December 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing desmoid fibrosis, feature, patient experience, pharma, rare disease
Lisa Pascoe lives with a rare, benign desmoid tumour in her abdomen. She opens up to Pharmafocus on her diagnosis …
Trump’s new FDA nominee advances in the Senate
December 4, 2019Research and Development Big Pharma, FDA, FDA commissioner, Trump, US Pharma
Dr Stephen Hahn, President Donald Trump’s FDA nominee, has advanced his nomination to the full Senate chamber. The vote was …
Male birth control drug may hold promise for treating lung cancer, Chinese study finds
December 4, 2019Research and Development Cancer Immunotherapy, Chinese Pharmaceuticals, Male Birth Control, lung cancer
A drug for male birth control may hold promise for treating lung cancer patients when treatments like immunotherapy do not …
FDA approves Johnson & Johnson cataract treatment
December 4, 2019Research and Development
Johnson & Johnson has secured approval from the FDA for its Tecnis Toris II 1-Piece Intraocular Lens (IOL). &nbs
Roche’s Tecentriq combo scores FDA approval in non-small cell lung cancer
December 4, 2019Research and Development, Sales and Marketing FDA, NSCLC, Roche, pharma, tecentriq
Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
